Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-849P is a processed pseudogene derived from the small nuclear RNA U6 gene[2][3][4][5]. The U6 snRNA itself plays a critical role in pre-mRNA splicing in eukaryotes as part of the spliceosome complex[1][3]. Pseudogenes like RNU6-849P are thought to arise from reverse transcription of mRNA and subsequent integration into the genome[4]. These sequences lack introns, regulatory elements, and biological activity; instead, they often bear features such as poly-A tails and disrupted alignment with the parent gene, confirming their nonfunctional status[2][4]. U6 pseudogenes are common within the genome and may harbor sequence repeats as described in some structural analyses[5]. Importantly, RNU6-849P itself does not encode a functional RNA or protein and has no known cellular role. Its presence may slightly complicate genomic annotation or variant calling in clinical genetic studies, but beyond that, they are generally biologically inert[2][4].
None (no drugs target this molecule as there is no defined mechanism)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 849, pseudogene (RNU6-849P).